Monday, December 03, 2018 8:38:50 AM
PR Newswire PR NewswireDecember 3, 2018
SAN JOSE, Calif., Dec. 3, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (ANIX), a biotechnology company focused on using the body's immune system to fight cancer, presented the latest data from its ongoing study focusing on early detection of breast cancer, utilizing Cchek™, its artificial intelligence (AI) driven cancer detection technology, at the American Association of Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy. The conference is designed to integrate multidisciplinary facets of basic cancer immunology and immunotherapy to broaden the understanding of ways to harness the immune system to address cancer. The conference was held November 27–30, 2018 in Miami Beach, Florida.
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
More
Anixa presented data demonstrating the ability of Cchek™ to identify the presence of early stage breast cancer in a subject by using its AI technology to analyze a simple blood draw. The Cchek™ technology demonstrated a sensitivity of 89.3% when detecting early stage breast cancer (Stage I or II) and a specificity (the ability to correctly identify healthy subjects) of 94.7% when used to test blinded samples. Furthermore, Cchek™ was also able to detect the early stages of breast cancer (Stage 0) in subjects with biopsy-confirmed ductal carcinoma in situ (DCIS), a type of pre-cancerous/non-invasive breast lesion that often leads to invasive breast cancer, with 72% sensitivity. The presentation is available on Anixa's website, or it may be requested by sending an email to AACR-TII-2018@anixa.com and including your name, title, and contact information.
"We are pleased to have made our presentation titled, Combining the immunophenotyping of MDSCs and lymphocytes with artificial intelligence (AI) to predict early stage breast cancer, at the AACR Tumor Immunology and Immunotherapy conference. This data was focused on using our Cchek™ technology to detect breast cancer in its early stages, primarily stage I and II when the cancer is more easily treated. The majority of screening technologies currently used for breast cancer detection, such as mammography, have the ability to detect later stage breast malignancies rather successfully but have shown difficulty with earlier stages. A major challenge with mammography is the large number of false positives resulting in overtreatment and many unnecessary biopsies," stated Dr. Amit Kumar, President and CEO of Anixa Biosciences. "As our study continues, we hope to enable a better approach for identifying breast cancer as early as possible including even when a non-invasive breast cancer lesion is present, such as in the case of DCIS. We have previously announced that our initial commercial focus is on a prostate cancer test for which we will be meeting with the USFDA on December 17, 2018. We recently presented our latest prostate cancer data at the 33rd Annual Meeting of The Society for Immunotherapy of Cancer (SITC)," added Dr. Kumar.
Recent ANIX News
- Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja • PR Newswire (US) • 05/06/2024 12:05:00 PM
- Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024 • PR Newswire (US) • 04/30/2024 11:45:00 AM
- Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board • PR Newswire (US) • 04/18/2024 12:20:00 PM
- Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties • PR Newswire (US) • 03/14/2024 12:45:00 PM
- Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress • PR Newswire (US) • 03/11/2024 12:00:00 PM
- Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial • PR Newswire (US) • 02/12/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/08/2024 09:15:32 PM
- Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference • PR Newswire (US) • 01/29/2024 01:50:00 PM
- Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology • PR Newswire (US) • 01/23/2024 12:55:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:08:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:07:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:07:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:05:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:05:16 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/16/2024 10:29:43 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/16/2024 09:43:17 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 01/16/2024 09:30:49 PM
- Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024 • PR Newswire (US) • 01/10/2024 02:00:00 PM
- Anixa Biosciences to Present at Biotech Showcase 2024 • PR Newswire (US) • 12/14/2023 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 11:01:47 AM
- Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine • PR Newswire (US) • 12/06/2023 11:00:00 PM
- Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine • PR Newswire (US) • 12/06/2023 09:05:00 PM
- Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology • PR Newswire (US) • 11/27/2023 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/02/2023 02:58:20 PM
- Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA) Ovarian Cancer National Conference • PR Newswire (US) • 10/31/2023 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM